Tilray Brands is projected to report consensus revenue of approximately $267.8 million and a loss per share of $0.18 for the quarter ended August 31, 2026, with the current stock price of $3.72 trading significantly below the average analyst target of $7.16.
Investors are primarily focused on the company’s expansion into the beverage alcohol market as a critical checkpoint for meeting its full-year 2027 Adjusted EBITDA guidance. Management is under pressure to prove that the recent BrewDog acquisition and cost-saving initiatives in U.S. beer can successfully offset legacy margin compression.
Supporting this outlook is the company's recent record revenue performance and growth in international medical cannabis sales, which rose 34% in the prior fiscal year. However, the stock continues to face headwinds from domestic volatility and persistent bottom-line losses due to ongoing uncertainty surrounding U.S. federal cannabis rescheduling.